VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Diagnosed epileptic patients of either sex with    │ Diagnosed epileptic patients of either sex with    │     100 │
│ age between 10-19 yrs (\<19yrs), coming to the     │ age between 10-19 yrs (<19yrs), coming to the      │         │
│ medicine Out Patient /In Patient Departments and   │ medicine Out Patient /In Patient Departments and   │         │
│ undergoing AED therapy for more than 6 months      │ undergoing AED therapy for more than 6 months      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Epileptics with high homocysteine levels i.e. \>   │ Epileptics with high homocysteine levels i.e. >    │     100 │
│ 10.9 µmol/L (Normal homocysteine levels are        │ 10.9 µmol/L (Normal homocysteine levels are        │         │
│ 4.3-9.9 µmol/L for male and 3.3-7.2 µmol/L for     │ 4.3-9.9 µmol/L for male and 3.3-7.2 µmol/L for     │         │
│ female adolescent and a high homocysteine          │ female adolescent and a high homocysteine          │         │
│ concentration is deaned as at least 11.4 µmol/L    │ concentration is deaned as at least 11.4 µmol/L    │         │
│ for male and at least 10.4 µmol/L for female.      │ for male and at least 10.4 µmol/L for female.      │         │
│ Gender mean of high homocysteine concentration is  │ Gender mean of high homocysteine concentration is  │         │
│ 10.9 µmol/L) \[5\]                                 │ 10.9 µmol/L) [5]                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy and lactation                            │ Pregnancy and lactation                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with diabetes, Ischemic heart disease     │ Patients with diabetes, Ischemic heart disease     │     100 │
│ (IHD), stroke, malignancy and psychiatric diseases │ (IHD), stroke, malignancy and psychiatric diseases │         │
│ are excluded from study                            │ are excluded from study                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients receiving vitamin supplements or who  │ The patients receiving vitamin supplements or who  │     100 │
│ had clinical evidence for an acute illness, renal  │ had clinical evidence for an acute illness, renal  │         │
│ dysfunction, thyroid dysfunction, chronic          │ dysfunction, thyroid dysfunction, chronic          │         │
│ inflammatory diseases, inborn errors of            │ inflammatory diseases, inborn errors of            │         │
│ homocysteine, cobalamin or folate metabolism, or   │ homocysteine, cobalamin or folate metabolism, or   │         │
│ any other condition known to interfere with        │ any other condition known to interfere with        │         │
│ homocysteine metabolism will be excluded           │ homocysteine metabolism will be excluded           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are already involved in any other     │ Patients who are already involved in any other     │     100 │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients not willing to fill consent/ assent form  │ Patients not willing to fill consent/ assent form  │     100 │
│ are also excluded from study                       │ are also excluded from study                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 19 Years │ Patients who are already involved in any other │      33 │
│                                   │ trial                                          │         │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 10 Years │ Patients who are already involved in any other │      35 │
│                                   │ trial                                          │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 85.33333333333333
OverAll Ratio: 91.16666666666666
